Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05929703
Other study ID # HUM00227397
Secondary ID DE-2022C1-25666
Status Recruiting
Phase N/A
First received
Last updated
Start date December 4, 2023
Est. completion date August 2027

Study information

Verified date February 2024
Source University of Michigan
Contact Eva Schmitt, PhD
Phone 617-971-5390
Email EvaSchmitt@hsl.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare the Hospital Elder Life Program (HELP) with a family-augmented version of HELP (FAM-HELP), that includes family members and care partners, for the prevention of delirium in older patients during hospital admission. The main objectives of the trial are the following: 1. To compare the effectiveness of FAM-HELP and HELP in reducing both the incidence of delirium and its severity. 2. To compare the effectiveness of FAM-HELP and HELP in improving patient- and family-reported outcomes. 3. To explore the implementation context, process, and outcomes of the FAM-HELP program in diverse hospital settings.


Description:

Delirium is a common complication of hospitalization and major surgery for older adults, and it can lead to loss of independence and substantial healthcare costs. One approach to preventing delirium is through the Hospital Elder Life Program (HELP). HELP personnel work to prevent delirium by providing orienting communication, assisting patients with walking and exercise, providing help with nutrition and fluids, implementing sleep protocols, and helping patients with vision and hearing aids. However, it is unknown whether involving family members in these activities along with HELP staff (i.e., "FAM-HELP") might be more effective with preventing delirium. The objective of this clinical trial is thus to compare the traditional HELP program with a family-augmented version of HELP (FAM-HELP) to determine which program is more effective with preventing delirium and related complications in older, hospitalized patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 3000
Est. completion date August 2027
Est. primary completion date May 2027
Accepts healthy volunteers No
Gender All
Age group 70 Years and older
Eligibility Inclusion Criteria: - Provision of informed consent - At least 70 years of age - Anticipated length of hospital stay at least 72 hours - Family member or care partner available to be on-site in the hospital - At least one delirium risk factor (e.g., cognitive or functional impairment, dehydration, vision or hearing impairment) Exclusion Criteria: - Delirium on admission - Unable to communicate verbally (e.g., coma, mechanical ventilation) - Unable to participate fully in interventions (e.g., terminal condition, advanced dementia) - Staff safety concerns (e.g., violent behavior) - Cardiac or intracranial surgery (due to competing causes of delirium)

Study Design


Intervention

Behavioral:
HELP
This is usual (standard) care across hospitals in this trial. A multidisciplinary team of nurse specialists, social workers, and volunteers implement daily protocols focused on orientation, cognitive stimulation, early mobilization, sleep enhancement, support with visual and hearing aids, mealtime assistance, hydration, reduction in polypharmacy, and nursing-based delirium prevention protocols.
FAM-HELP
Family members and care partners will provide daily emotional and social support during hospitalization. Additionally, family members and care partners will engage in HELP-based protocols throughout the day. The rationale for this protocol augmentation is two-fold: (1) HELP may not consistently have available volunteers (e.g., short-staffing) during a hospital stay, and (2) patients may be more likely to engage in therapeutic activities with a family member given the connection and comfort level.

Locations

Country Name City State
United States Michigan Medicine Ann Arbor Michigan
United States Meriter Hospital Madison Wisconsin
United States Saddleback Medical Center Orange California
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania
United States Allegheny General Hospital Pittsburgh Pennsylvania
United States MaineHealth Portland Maine
United States University of Utah Salt Lake City Utah

Sponsors (11)

Lead Sponsor Collaborator
University of Michigan Brandeis University, Hebrew SeniorLife, Indiana University, MaineHealth, MemorialCare Saddleback Medical Center, Patient-Centered Outcomes Research Institute, UnityPoint Health - Meriter Hospital, University of Pennsylvania, University of Utah, West Penn Allegheny Health System

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Antipsychotic use Proportion of participants in each group (%) requiring antipsychotic medications during hospitalization Day of trial enrollment through day of hospital discharge, up to 14 days
Other Restraint use Proportion of participants in each group (%) requiring restraint use during hospitalization Day of trial enrollment through day of hospital discharge, up to 14 days
Primary Delirium Incidence Any positive delirium screen (yes/no) as determined by the long-form Confusion Assessment Method (CAM) Day of trial enrollment through day of hospital discharge, up to 14 days
Primary Delirium Severity Delirium severity score will be recorded using the Confusion Assessment Method Long Form Severity Score (CAM-S) (n, 0-19, with higher number indicating more severe delirium) Day of trial enrollment through day of hospital discharge, up to 14 days
Secondary Delirium Duration The cumulative number of days (n) with a positive delirium screen will be calculated for all participants Day of trial enrollment through day of hospital discharge, up to 14 days
Secondary Persistent Delirium Positive delirium screen (yes/no) 30 days after hospital discharge as determined by the long-form Confusion Assessment Method (AM) 30 days after hospital discharge
Secondary Delirium Burden - Patient Delirium burden will be calculated using the Patient Delirium Burden Scale (DEL-B-P) (n, 0-40, with higher number indicating more severe burden) Day of trial enrollment through 30 days after discharge
Secondary Delirium Burden - Family and Care Partners Delirium burden will be calculated using the Patient Delirium Family Caregiver Scale (DEL-B-C) (n, 0-40, with higher number indicating more severe burden) Day of trial enrollment through 30 days after discharge
Secondary Caregiving Strain Strain associated with patient caregiving will be assessed via Modified Caregiver Strain Index (MCSI) (n, 0-26, with higher number indicating more caregiver strain) Hospital discharge through 30 days after discharge
Secondary Cognitive Function - Subjective Reporting Subjective reporting of cognitive function will be assessed via PROMIS Cognitive Function - Short Form 6a (n, 6-30, with higher number indicating better subjective cognitive function) Hospital discharge through 30 days after discharge
Secondary Hospital Experience Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey (n, 7-28, with higher score indicating better hospital experience) Day of hospital discharge (typically up to 30 days after hospital admission, may extend to 60 or more days)
Secondary Global Health Assessment of overall physical and mental health via PROMIS Global Health-10. Two separate subscales will be calculated, Global Physical Health (n, 4-20) and Global Mental Health (n, 4-20), with higher scores indicating better health. Hospital discharge through 30 days after discharge
Secondary Physical Function Assessment of physical function via PROMIS Physical Short Form 10a (n, 10-50, with higher scores indicating better physical function). 30 days after hospital discharge
Secondary Falls Proportion of participants in each group (%) experiencing at least one fall Day of trial enrollment through 30 days after hospital discharge
Secondary Length of Hospital Stay Total number of days (n) spent in the hospital Day of hospital admission through hospital discharge (typically up to 30 days after hospital admission, may extend to 60 or more days)
Secondary Discharge Disposition Proportion of patients in each group (%) discharged somewhere other than home (e.g., Long-Term Care Facility) Day of hospital discharge through 30 days after discharge
Secondary 30-Day Readmission Proportion of participants in each group (%) requiring hospital readmission Day of hospital discharge through 30 days after discharge
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A